-
Under the steady growth of the market, the API industry will usher in new opportunities for development
Time of Update: 2022-02-19
In addition to the continuous growth of the market, according to Claricate data, China currently has 1,482 API production bases.
In this context, domestic API companies should accelerate innovation and promote the transformation and upgrading of the industry towards green, low-carbon and high-quality development .
-
The market of traditional Chinese medicine formula granules ushered in new opportunities, and the upstream "shovel sellers" can be tapped
Time of Update: 2022-02-19
With the completion of the pilot program of traditional Chinese medicine formula granules, the industry expects that the market will embrace new opportunities, and its upstream "shovel sellers" are also excavable .
-
The market of Chinese medicine decoction pieces is about to explode, and these problems need to be solved urgently
Time of Update: 2022-02-19
In addition, it is worth mentioning that under the current promotion of national policies, various localities are also beginning to improve the quality control system of local Chinese herbal decoction pieces, and revise the relevant Chinese herbal medicine decoction pieces processing specifications .
-
Fosun Pharma Subsidiary Launches Phase 3 Clinical Trials of 2 New Drugs in China
Time of Update: 2022-02-19
Retrieved Jan 20, 2022, from http:// 2022-01-20[3] Fuchuang Medicine's new anti-tumor drug CDK4/6 inhibitor, the first patient in the US Phase I clinical trial.
-
Gilead reveals again: $250 million in counterfeit AIDS drugs flowed into the U.S. market
Time of Update: 2022-02-18
In two years, 85,247 bottles of counterfeit versions of the two drugs were sold, worth about $250 million;In the first half of 2021, the Food and Drug Administration investigated and dealt with 3,958 cases of production, sale and use of counterfeit and inferior drugs, worth 38.
-
The pharmaceutical equipment industry has started a new journey, and the transformation and upgrading are accelerating
Time of Update: 2022-02-18
It is worth noting that due to the current diversified development of domestic pharmaceutical equipment companies mainly reflected in the adjustment of product lines, the extension of the industrial chain and the improvement of services; affected by this, high-end and intelligent models have become numerous.
-
The major pharmaceutical province issued a document that Chinese herbal decoction pieces can be sold at a 25% price increase!
Time of Update: 2022-02-18
In the "Opinions on Further Rectifying the Price Order of the Drug and Medical Services Market" issued by the National Development and Reform Commission and other 8 departments earlier, it was clarified that the increase rate of traditional Chinese medicine pieces should be controlled at 25% Within, shall not exceed the markup rate sales .
-
Advanced tumors are expected to usher in more new drugs!
Time of Update: 2022-02-18
For example, on January 19, Fosun Pharma announced that HLX208, a small-molecule inhibitor targeting human BRAF protein V600E mutation, has been approved for clinical trials of single-agent or combination therapy for advanced solid tumors .
-
Domestic innovative drugs usher in a big outbreak, where is the way out for generic drugs?
Time of Update: 2022-02-18
In this regard, analysts believe that generic drugs will still be the focus of the development of the domestic pharmaceutical industry for a long time in the future, and there will still be a broad market .
-
In 2021, my country's human vaccine exports will increase from 1.9 billion to 101 billion, mostly from the export of new crown vaccines
Time of Update: 2022-02-18
According to customs data, the export value of human vaccines in 2021 is about 101 billion yuan, an increase of 5,264.
In addition, according to customs data, the export volume of human vaccines in 2021 is about 4,996 tons, an increase of 2,950.
-
700% growth rate can't beat centralized procurement?
Time of Update: 2022-02-18
Lundbeck, Pfizer, and Eli Lilly, which occupy a huge market share in antidepressants, almost all chose to maintain their own price system and gave up the bid for centralized procurement .
-
The annual report performance of 8 pharmaceutical companies is good!
Time of Update: 2022-02-18
The 2021 annual report performance forecast disclosed by Hualan shares shows that it is expected to achieve a net profit of 200 million to 240 million yuan in 2021, an increase of 145.
-
In 2022, the pharmaceutical equipment industry is ready to start a new journey!
Time of Update: 2022-02-18
"The past 2021 has been a year for the company to accumulate strength . We have made important upgrades in equipment and hardware, and have also made major breakthroughs in the field of testing. Sa
-
3 months a shot!
Time of Update: 2022-02-18
After meeting its primary endpoint at month 9, the trial met all of its secondary endpoints at month 18, hereditary transthyretin amyloidosis polyneuropathy (hATTR-PN) compared with placebo in adults Patients showed significant improvements in multiple measures including neuropathic impairment, quality of life (QoL), gait speed, nutritional status, and overall disability .
-
Kangtai Biological Subsidiary received the notification of on-site verification of the registration of freeze-dried human rabies vaccine
Time of Update: 2022-02-18
On January 24, Kangtai Biological announced that the company's wholly-owned subsidiary, Minhai Biological, has recently received a CDE notice that it needs to start drug registration verification for the freeze-dried human rabies vaccine (human diploid cells) declared and registered by Minhai Biological.
Freeze-dried human rabies vaccine (human diploid cells) for the prevention of rabies .
-
The 5 billion antihypertensive drug market has ushered in strong competitors
Time of Update: 2022-02-18
Recently, Guangzhou Poinsettia Pharmaceuticals issued an announcement stating that its valsartan oral solution, which was reported to be produced as a generic class 3 product, has entered the stage of administrative approval .
-
This drug is listed as a second-class protected species of traditional Chinese medicine!
Time of Update: 2022-02-18
Among them, Xiaoer Resuqing Syrup, which is listed as the second-class protected variety, is also the modern Chinese medicine variety that Zhenbaodao Pharmaceutical has long adhered to the innovative research and development of traditional Chinese medicine varieties, and has developed through continuous exploration and practice .
-
China's oncology drug market has exceeded 140 billion. How should local pharmaceutical companies seize the opportunity?
Time of Update: 2022-02-18
In recent years, with the release of some policies to support pharmaceutical innovation such as centralized procurement and consistency evaluation, coupled with the continuous growth of market demand, China's oncology drug industry has ushered in opportunities for rapid development .
-
Domestic innovative drugs usher in a blowout period, and these areas will become the main driving force
Time of Update: 2022-02-18
In recent years, with the reform of the national drug review and approval system, the injection of a large amount of high-quality capital is bringing more and more development momentum to the Chinese pharmaceutical industry .
-
A large number of pharmaceutical companies are busy divesting assets!
Time of Update: 2022-02-18
. On January 7, Shuangcheng Pharmaceutical announced that it agreed that Ningbo Shuangcheng Pharmaceutical, a holding subsidiary of the company, plans to acquire specific intellectual property rights and production technologies related to memantine hydrochloride tablets (5mg, 10mg) for RMB 6 million.
